• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

佛罗里达州中部最大医疗系统中重症 COVID-19 患者的 ICU 结局和生存率。

ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida.

机构信息

Division of Critical Care - AdventHealth Medical Group, AdventHealth Orlando, Orlando, Florida, United States of America.

Internal Medicine Residency Program, AdventHealth Orlando, Orlando, Florida, United States of America.

出版信息

PLoS One. 2021 Mar 25;16(3):e0249038. doi: 10.1371/journal.pone.0249038. eCollection 2021.

DOI:10.1371/journal.pone.0249038
PMID:33765049
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7993561/
Abstract

BACKGROUND

Observational studies have consistently described poor clinical outcomes and increased ICU mortality in patients with severe coronavirus disease 2019 (COVID-19) who require mechanical ventilation (MV). Our study describes the clinical characteristics and outcomes of patients with severe COVID-19 admitted to ICU in the largest health care system in the state of Florida, United States.

METHODS

Retrospective cohort study of patients admitted to ICU due to severe COVID-19 in AdventHealth health system in Orlando, Florida from March 11th until May 18th, 2020. Patients were characterized based on demographics, baseline comorbidities, severity of illness, medical management including experimental therapies, laboratory markers and ventilator parameters. Major clinical outcomes analyzed at the end of the study period were: hospital and ICU length of stay, MV-related mortality and overall hospital mortality of ICU patients.

RESULTS

Out of total of 1283 patients with COVID-19, 131 (10.2%) met criteria for ICU admission (median age: 61 years [interquartile range (IQR), 49.5-71.5]; 35.1% female). Common comorbidities were hypertension (84; 64.1%), and diabetes (54; 41.2%). Of the 131 ICU patients, 109 (83.2%) required MV and 9 (6.9%) received ECMO. Lower positive end expiratory pressure (PEEP) were observed in survivors [9.2 (7.7-10.4)] vs non-survivors [10 (9.1-12.9] p = 0.004]. Compared to non-survivors, survivors had a longer MV length of stay (LOS) [14 (IQR 8-22) vs 8.5 (IQR 5-10.8) p< 0.001], Hospital LOS [21 (IQR 13-31) vs 10 (7-1) p< 0.001] and ICU LOS [14 (IQR 7-24) vs 9.5 (IQR 6-11), p < 0.001]. The overall hospital mortality and MV-related mortality were 19.8% and 23.8% respectively. After exclusion of hospitalized patients, the hospital and MV-related mortality rates were 21.6% and 26.5% respectively.

CONCLUSIONS

Our study demonstrates an important improvement in mortality of patients with severe COVID-19 who required ICU admission and MV in comparison to previous observational reports and emphasizes the importance of standard of care measures in the management of COVID-19.

摘要

背景

观察性研究一致描述了患有严重 2019 年冠状病毒病(COVID-19)并需要机械通气(MV)的患者的临床结局较差和 ICU 死亡率增加。我们的研究描述了在美国佛罗里达州最大的医疗保健系统中因严重 COVID-19 而入住 ICU 的患者的临床特征和结局。

方法

这是一项回顾性队列研究,研究对象为 2020 年 3 月 11 日至 5 月 18 日期间因严重 COVID-19 入住佛罗里达州奥兰多 AdventHealth 卫生系统 ICU 的患者。根据人口统计学、基线合并症、疾病严重程度、包括实验性治疗在内的医疗管理、实验室标志物和呼吸机参数对患者进行特征描述。在研究结束时分析了主要临床结局:医院和 ICU 住院时间、MV 相关死亡率和 ICU 患者的总体医院死亡率。

结果

在总共 1283 例 COVID-19 患者中,有 131 例(10.2%)符合 ICU 入住标准(中位年龄:61 岁[四分位距(IQR),49.5-71.5];35.1%为女性)。常见的合并症包括高血压(84 例;64.1%)和糖尿病(54 例;41.2%)。在 131 例 ICU 患者中,109 例(83.2%)需要 MV,9 例(6.9%)接受 ECMO。与非幸存者相比,幸存者的呼气末正压(PEEP)较低[9.2(7.7-10.4)]vs 非幸存者 [10(9.1-12.9] p = 0.004]。与非幸存者相比,幸存者的 MV 持续时间(LOS)更长[14(IQR 8-22)vs 8.5(IQR 5-10.8)p < 0.001]、医院 LOS 更长[21(IQR 13-31)vs 10(7-1)p < 0.001]和 ICU LOS 更长[14(IQR 7-24)vs 9.5(IQR 6-11),p < 0.001]。总体医院死亡率和 MV 相关死亡率分别为 19.8%和 23.8%。排除住院患者后,医院和 MV 相关死亡率分别为 21.6%和 26.5%。

结论

与之前的观察性报告相比,我们的研究表明需要 ICU 入院和 MV 的严重 COVID-19 患者的死亡率有了显著提高,这强调了在 COVID-19 管理中标准治疗措施的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67e9/7993561/bbc62ba55365/pone.0249038.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67e9/7993561/bbc62ba55365/pone.0249038.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67e9/7993561/bbc62ba55365/pone.0249038.g001.jpg

相似文献

1
ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida.佛罗里达州中部最大医疗系统中重症 COVID-19 患者的 ICU 结局和生存率。
PLoS One. 2021 Mar 25;16(3):e0249038. doi: 10.1371/journal.pone.0249038. eCollection 2021.
2
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.意大利伦巴第地区 1591 名 ICU 收治的 SARS-CoV-2 感染患者的基线特征和结局。
JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394.
3
Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.意大利伦巴第地区重症监护病房中 COVID-19 患者死亡的相关危险因素。
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355. doi: 10.1001/jamainternmed.2020.3539.
4
Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study.加拿大疫情第一阶段住院和重症监护的 COVID-19 患者的特征和结局:一项全国性队列研究。
CMAJ Open. 2021 Mar 8;9(1):E181-E188. doi: 10.9778/cmajo.20200250. Print 2021 Jan-Mar.
5
Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study.4244 例危重症 COVID-19 成年患者的临床特征和第 90 天结局:一项前瞻性队列研究。
Intensive Care Med. 2021 Jan;47(1):60-73. doi: 10.1007/s00134-020-06294-x. Epub 2020 Oct 29.
6
Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review.COVID-19 感染危重症患者的临床病程和结局:系统评价。
Clin Microbiol Infect. 2021 Jan;27(1):47-54. doi: 10.1016/j.cmi.2020.10.017. Epub 2020 Oct 23.
7
Global Impact of Coronavirus Disease 2019 Infection Requiring Admission to the ICU: A Systematic Review and Meta-analysis.全球 2019 年冠状病毒病感染需入住 ICU 的影响:系统评价和荟萃分析。
Chest. 2021 Feb;159(2):524-536. doi: 10.1016/j.chest.2020.10.014. Epub 2020 Oct 15.
8
Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study.阿根廷 COVID-19 有创通气患者的临床特征和结局(SATICOVID):一项前瞻性、多中心队列研究。
Lancet Respir Med. 2021 Sep;9(9):989-998. doi: 10.1016/S2213-2600(21)00229-0. Epub 2021 Jul 2.
9
Multisystem outcomes and predictors of mortality in critically ill patients with COVID-19: Demographics and disease acuity matter more than comorbidities or treatment modalities.新冠肺炎危重症患者的多系统结局和死亡率预测因素:人口统计学和疾病严重程度比合并症或治疗方式更重要。
J Trauma Acute Care Surg. 2021 May 1;90(5):880-890. doi: 10.1097/TA.0000000000003085.
10
Prevalence and outcomes of atrial fibrillation in patients hospitalized with COVID-19.COVID-19 住院患者心房颤动的患病率和结局。
Curr Med Res Opin. 2024 Sep;40(9):1477-1481. doi: 10.1080/03007995.2024.2378179. Epub 2024 Jul 26.

引用本文的文献

1
Robust COVID-19 Vaccine Responses Despite Filarial Co-Infection: Insights from a Lymphatic Filariasis Cohort in Ghana.尽管存在丝虫共感染,但COVID-19疫苗反应依然强劲:来自加纳淋巴丝虫病队列的见解。
Vaccines (Basel). 2025 Mar 13;13(3):312. doi: 10.3390/vaccines13030312.
2
PDE4B Modulates Phosphorylation of p65 (Ser468) via cAMP/PKA in Acute Lung Injury.磷酸二酯酶4B(PDE4B)在急性肺损伤中通过环磷酸腺苷/蛋白激酶A(cAMP/PKA)调节p65(Ser468)的磷酸化。
Lung. 2025 Feb 16;203(1):33. doi: 10.1007/s00408-025-00787-6.
3
Impact of low dose inhaled nitric oxide treatment in spontaneously breathing and intubated COVID-19 patients: a retrospective propensity-matched study.

本文引用的文献

1
COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City.COVID-19 肺部病理学:来自意大利和纽约市的多机构尸检队列研究。
Mod Pathol. 2020 Nov;33(11):2156-2168. doi: 10.1038/s41379-020-00661-1. Epub 2020 Sep 2.
2
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
3
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
低剂量吸入一氧化氮治疗有自主呼吸和插管的 COVID-19 患者的影响:一项回顾性倾向评分匹配研究。
Crit Care. 2024 Oct 25;28(1):344. doi: 10.1186/s13054-024-05093-w.
4
Efficacy and safety of a novel antiviral herbal preparation in ICU-admitted patients with COVID-19: A phase III double-blinded controlled trial.一种新型抗病毒草药制剂用于新冠肺炎重症监护病房患者的疗效与安全性:一项III期双盲对照试验。
Avicenna J Phytomed. 2024 Mar-Apr;14(2):215-228. doi: 10.22038/AJP.2023.23259.
5
Healthcare utilization 9 months pre- and post- COVID-19 hospitalization among patients discharged alive.COVID-19 住院患者出院后 9 个月的医疗保健利用情况。
PLoS One. 2024 Jun 20;19(6):e0303509. doi: 10.1371/journal.pone.0303509. eCollection 2024.
6
Estimates of SARS-CoV-2 Hospitalization and Fatality Rates in the Prevaccination Period, United States.美国未接种疫苗时期 SARS-CoV-2 住院和死亡率的估计。
Emerg Infect Dis. 2024 Jun;30(6):1144-1153. doi: 10.3201/eid3006.231285.
7
The COVID-19 Tracheostomy Experience at a Large Academic Medical Center in New York during the First Year.纽约一家大型学术医疗中心第一年的新冠气管造口术经验
J Clin Med. 2024 Apr 7;13(7):2130. doi: 10.3390/jcm13072130.
8
Predictors of Mortality and Orotracheal Intubation in Patients with Pulmonary Barotrauma Due to COVID-19: An Italian Multicenter Observational Study during Two Years of the Pandemic.COVID-19所致肺气压伤患者死亡率和经口气管插管的预测因素:一项意大利多中心在大流行两年期间的观察性研究
J Clin Med. 2024 Mar 15;13(6):1707. doi: 10.3390/jcm13061707.
9
Clinical Course and Outcomes of COVID-19 Patients Admitted to the ICU of a Tertiary Care Hospital in Central India: A Cross-Sectional Study.印度中部一家三级护理医院重症监护病房收治的新冠肺炎患者的临床病程及结局:一项横断面研究
Cureus. 2024 Feb 23;16(2):e54744. doi: 10.7759/cureus.54744. eCollection 2024 Feb.
10
Correlation between interleukin-6 expression in post-mortem core liver biopsy and degree of liver injury in patients with fatal COVID-19.新冠死亡患者尸检肝脏活检核心组织中白细胞介素-6表达与肝损伤程度的相关性
Narra J. 2023 Dec;3(3):e463. doi: 10.52225/narra.v3i3.463. Epub 2023 Dec 6.
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
4
Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature.重症监护病房中新冠肺炎患者的死亡率:对新出现文献的系统评价
Crit Care. 2020 Jun 4;24(1):285. doi: 10.1186/s13054-020-03006-1.
5
Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019.严重 COVID-19 高凝状态下常规静脉血栓栓塞预防可能不足。
Crit Care Med. 2020 Sep;48(9):e783-e790. doi: 10.1097/CCM.0000000000004466.
6
Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study.加利福尼亚州和华盛顿州严重 2019 冠状病毒病的发病率、临床结局和传播动态:前瞻性队列研究。
BMJ. 2020 May 22;369:m1923. doi: 10.1136/bmj.m1923.
7
Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.《纽约市 COVID-19 重症成人的流行病学、临床病程和结局:一项前瞻性队列研究》
Lancet. 2020 Jun 6;395(10239):1763-1770. doi: 10.1016/S0140-6736(20)31189-2. Epub 2020 May 19.
8
Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.托珠单抗治疗 COVID-19 患者的临床结局:一项个体患者数据系统评价。
J Med Virol. 2020 Nov;92(11):2516-2522. doi: 10.1002/jmv.26038. Epub 2020 Jun 9.
9
Effects of temperature variation and humidity on the death of COVID-19 in Wuhan, China.温度变化和湿度对中国武汉 COVID-19 死亡的影响。
Sci Total Environ. 2020 Jul 1;724:138226. doi: 10.1016/j.scitotenv.2020.138226. Epub 2020 Mar 26.
10
Noninvasive Versus Invasive Ventilation in COVID-19: One Size Does Not Fit All!新型冠状病毒肺炎中无创通气与有创通气的应用:并非一概而论!
Anesth Analg. 2020 Aug;131(2):e114-e115. doi: 10.1213/ANE.0000000000004943.